Detalhe da pesquisa
1.
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Nature
; 608(7921): 199-208, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35859180
2.
Author Correction: The evolutionary history of lethal metastatic prostate cancer.
Nature
; 584(7820): E18, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728210
3.
The evolutionary history of lethal metastatic prostate cancer.
Nature
; 520(7547): 353-357, 2015 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25830880
4.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Lancet Oncol
; 20(12): 1730-1739, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727538
5.
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
J Pathol
; 246(2): 244-253, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30015382
6.
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
Br J Cancer
; 119(3): 347-356, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29988112
7.
Segmentum: a tool for copy number analysis of cancer genomes.
BMC Bioinformatics
; 18(1): 215, 2017 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28407731
8.
Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.
BMC Cancer
; 17(1): 310, 2017 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28468611
9.
MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2.
Prostate
; 75(8): 798-805, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25731699
10.
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours.
J Pathol
; 232(1): 4-15, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24588013
11.
Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network.
Proc Natl Acad Sci U S A
; 109(9): 3475-80, 2012 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22345562
12.
Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human glioma.
J Pathol
; 229(3): 449-59, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23007860
13.
Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Life Sci Alliance
; 7(6)2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580393
14.
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
J Natl Cancer Inst
; 116(1): 115-126, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676819
15.
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.
Nat Cancer
; 5(1): 114-130, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177459
16.
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Nat Commun
; 15(1): 1828, 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418825
17.
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 29(15): 2835-2844, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36996325
18.
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Acta Neuropathol Commun
; 11(1): 176, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37932833
19.
Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy.
Eur Urol Oncol
; 5(6): 677-686, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895867
20.
PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
Sci Rep
; 12(1): 14083, 2022 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35982066